Raymond James & Associates Amarin Corp Plcuk Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Raymond James & Associates holds 33,784 shares of AMRN stock, worth $18,581. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,784
Previous 34,884
3.15%
Holding current value
$18,581
Previous $24,000
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding AMRN
# of Institutions
176Shares Held
65.1MCall Options Held
258KPut Options Held
98K-
Sarissa Capital Management LP Greenwich, CT24.9MShares$13.7 Million3.89% of portfolio
-
Kynam Capital Management, LP Princeton, NJ12.4MShares$6.83 Million0.64% of portfolio
-
Eversept Partners, LP New York, NY3.31MShares$1.82 Million0.16% of portfolio
-
Morgan Stanley New York, NY2.55MShares$1.4 Million0.0% of portfolio
-
Scp Investment, LP2.5MShares$1.38 Million1.16% of portfolio
About AMARIN CORP PLCUK
- Ticker AMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 403,206,016
- Market Cap $222M
- Description
- Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...